Andy Yu is an associate in Quinn Emanuel’s Los Angeles office. He joined the firm in 2024. His practice focuses on intellectual property litigation. With a PhD in bioinformatics and statistics and years of industry experiences, Andy represents high-tech and life sciences clients in patent litigation at the International Trade Commission and federal district courts. He has handled various matters involving complex technology such as graphics processors, memory modules, microprocessors, LCD displays, operating system, and software. He has litigated Hatch-Waxman cases on behalf of brand pharmaceutical companies and evaluated ANDA strategies for generics. He also has significant experiences in prosecuting patents and evaluating patent portfolios.
Prior to joining Quinn Emanuel, Andy was General Counsel at a startup biotech, where he oversaw the company’s patent strategy and portfolio development and successfully led the company to secure two rounds of financing exceeding $30M. Prior to that, he practiced patent litigation at two other law firms. Prior to attending law school, Andy worked as a software engineer at SAS Institute and a senior research biostatistician at Merck.
- Northwestern University School of Law
(J.D., cum laude, 2011) - North Carolina State University
(Ph.D. Bioinformatics and Statistics, 2004)- Phi Kappa Phi
- University of Science and Technology of China
(B.S. Biology, 1999)
- The State Bar of New York
- The State Bar of New Jersey
- The State Bar of Texas
- The State Bar of Massachusetts
- The State Bar of the District of Columbia
- United States Patent and Trademark Office
- Chinese
- Yu X, Chatterji A. (2011) Why Brand Pharmaceutical Companies Choose to Pay Generics in Settling Patent Disputes – A Systematic Evaluation of the Asymmetric Risks in Litigation. 10 Nw J Tech & Intell Prop 19 (cited in the Amicus Brief by Kirkland & Ellis submitted to the Supreme Court for FTC v. Actavis, 570 U.S. 136 (2013))
- Reiser V, Smith RC, Xue J, Kurtz MM, Liu R, Le Grand SB, He X, Yu X, Wong PH, Hinchcliffe JS, Tanen MR, Lazar G, Zieba R, Ichetovkin M, Chen Z, Tanaka WK, Marton MJ, Liao J, Morris M, Hailman EP, Tokiwa G, Plump AS. (2011) Biomarker Approach for High-throughput Simultaneous Analysis of Gene, Protein and Lipid Profiles in Heterogeneous Tissue Specimens. Clin Chem 57(11): 1545-1555
- Puig O, Yuan J, Stepaniants S, Zieba R, Zycband E, Morris M, Coulter S, Yu X, Menke J, Woods J, Chen F, Ramey D, He X, O’Neil E, Hailman EP, Johns D, Hubbard B, Lum P, Wright S, DeSouza M, Plump AS, Reiser V. (2011) A Gene Expression Signature That Classifies Human Atherosclerotic Plaque by Relative Inflammation Status. Circ: Cardiovasc Genet 4: 595-604
- Chatterji A, Yu X. (2010) Impact of Reverse Exclusionary Settlements on Consumer Welfare: A Law and Economic Analysis. Antitrust Health Care Chronicle 23(4): 2-6
- Yu X, Wan S, Wong PH. (2009) Testing Biological Processes in Microarray Experiments Using Pre-defined Gene Sets. JSM Proc 2009: 3639-3653
- Wan S, Yu X, Wong PH. (2008) Better Prognosis by Multiple-gene Classifier with Pair Information. JSM Proc 2008: 3289-3296
- Yu X, Chu TM, Gibson G, Wolfinger RD. (2004) A Mixed Model Approach to Identify Yeast Transcriptional Regulatory Motifs via Microarray Experiments. Stat Appl Genet Mol Biol 3(2): Art 22
- Czika W, Yu X. (2004) Gene Frequencies and Hardy-Weinberg Disequilibrium. In Genetic Analysis of Complex Traits Using SAS. SAS Publishing
- Czika W, Yu X and Wolfinger RD. (2002) An Introduction to Genetic Data Analysis Using SAS/Genetics. SUGI Proc 2002
- Yu X, Warner JR. (2001) Expression of a Micro-protein. J Biol Chem 276(36): 33821-33825
- Zhai Q, Ji H, Zheng Z, Yu X, Sun L, Liu X. (2000) Copper Induces Apoptosis in BA/F3β Cells: Bax, Reactive Oxygen Species, and NFκB Are Involved. J Cell Physiol 184(2): 161-170
Patents
- Quality control product for detecting fragmented DNA (Deoxyribonucleic Acid) mutation and preparation method thereof. CN107475387B.
- Method and library construction kit for target gene enrichment. CN108004301B.